comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acutelymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia

Frontiers of Medicine 2022, Volume 16, Issue 1,   Pages 139-149 doi: 10.1007/s11684-021-0835-8

Keywords： B-cell acute lymphoblastic leukemia     bispecific antibody     trispecific antibody     CD19     CD20    

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Frontiers of Medicine 2012, Volume 6, Issue 4,   Pages 416-420 doi: 10.1007/s11684-012-0224-4

Keywords： acute lymphoblastic leukemia     early T precursor     prognosis    

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Keywords： acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy    

Venous thromboembolism in children with acute lymphoblastic leukemia in China: a report from the Chinese

Frontiers of Medicine 2023, Volume 17, Issue 3,   Pages 518-526 doi: 10.1007/s11684-022-0958-6

Keywords： acute lymphoblastic leukemia     child     venous thromboembolism     epidemiology     clinical characteristic     risk    

Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2015, Volume 9, Issue 1,   Pages 1-9 doi: 10.1007/s11684-015-0381-3

Keywords： pharmacogenomics     acute lymphoblastic leukemia     genomics     pharmacogenetics    

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 442-458 doi: 10.1007/s11684-021-0877-y

Keywords： T-cell acute lymphoblastic leukemia     HDAC inhibitor     chidamide     NOTCH1     MYC     ubiquitination    

imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acutelymphoblastic leukemia

Yinjun Lou, Yafang Ma, Chenyin Li, Sansan Suo, Hongyan Tong, Wenbin Qian, Wenyuan Mai, Haitao Meng, Wenjuan Yu, Liping Mao, Juyin Wei, Weilei Xu, Jie Jin

Frontiers of Medicine 2017, Volume 11, Issue 2,   Pages 229-238 doi: 10.1007/s11684-017-0506-y

Keywords： Philadelphia chromosome     acute lymphoblastic leukemia     imatinib     CALLG2008    

Molecular pathogenesis of acute myeloid leukemia: A diverse disease with new perspectives

Felicitas THOL, Arnold GANSER

Frontiers of Medicine 2010, Volume 4, Issue 4,   Pages 356-362 doi: 10.1007/s11684-010-0220-5

Keywords： acute myeloid leukemia     mutations     risk stratification    

Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research

Jiong HU

Frontiers of Medicine 2011, Volume 5, Issue 1,   Pages 45-52 doi: 10.1007/s11684-011-0117-y

Keywords： acute promyelocytic leukemia     arsenic     all-trans retinoic acid     survival    

FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches

Frontiers of Medicine 2022, Volume 16, Issue 6,   Pages 896-908 doi: 10.1007/s11684-022-0944-z

Keywords： acute myeloid leukemia     FGF13     prognosis     immune-related genes     bone marrow niches    

expression pattern of mutations coordinated by target repression and promoter hypermethylation in acutemyeloid leukemia

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 627-636 doi: 10.1007/s11684-020-0815-4

Keywords： RUNX1     gene mutation     acute myeloid leukemia     transcriptional repression     DNA methylation    

Diagnosis-related Groups (DRGs)-based payment reform to bring benefits to patient care: A case study of leukemia

Zhi-Ruo ZHANG PhD, Jian-Qing MI MD, Zhao-Jun WEN MA, Sai-Juan CHEN MD, PhD, Zhu CHEN PhD, Long-Jun GU MD, Jing-Yan TANG MD, PhD, Shu-Hong SHEN MD, PhD,

Frontiers of Medicine 2010, Volume 4, Issue 1,   Pages 8-15 doi: 10.1007/s11684-010-0018-5

Keywords： healthcare reform     diagnosis-related groups     clinical paths     comparative effectiveness analysis     acute promyelocyticleukemia     childhood acute lymphoblastic leukemia    

Predictive values of plasma TNFα and IL-8 for intracranial hemorrhage in patients with acute promyelocyticleukemia

Frontiers of Medicine 2022, Volume 16, Issue 6,   Pages 909-918 doi: 10.1007/s11684-021-0890-1

Keywords： acute promyelocytic leukemia     intracranial hemorrhage     cytokines     biomarker    

ACSL5, a prognostic factor in acute myeloid leukemia, modulates the activity of Wnt/-catenin signaling

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 685-698 doi: 10.1007/s11684-022-0942-1

Keywords： acute myeloid leukemia     acyl-CoA synthetase long chain family member 5     Wnt3a     palmitoylation     ABT-199    

unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acuteleukemia post-chemotherapy plus modified donor lymphocyte infusion

Frontiers of Medicine 2021, Volume 15, Issue 5,   Pages 728-739 doi: 10.1007/s11684-021-0833-x

Keywords： second hematopoietic stem cell transplantation     acute leukemia     relapse     chemotherapy     modified donor